Hormone Therapy for Breast Cancer in Men American Cancer Society

Castration resistance during the follow-up period was identified by a claim for castration resistance, a change in treatment, and a record of rising PSA if available. Androgen-deprivation therapy (ADT) was the standard of care for mCSPC for many decades5. The availability of androgen receptor pathway inhibitors (ARPIs – apalutamide APA, enzalutamide ENZ, darolutamide DARO, abiraterone acetate plus prednisone AAP) has promoted rapid evolution of the treatment landscape and improved patient outcomes6. Upfront ARPI combination therapy has become the standard of care, replacing ADT and combined antigen blockade (CAB) alone12,13.

Men should engage in regular blood work as part of their treatment plan, discussing results with their healthcare providers to make informed decisions about their health. The need for an AI in androgen therapy depends on individual estrogen sensitivity and baseline hormone levels. Some men maintain a balanced androgen-to-estrogen ratio despite TRT, while others experience excessive aromatization requiring intervention. Clinical data indicate that excessive estrogen suppression can cause joint discomfort, lipid profile changes, and cardiovascular issues. A study in The Journal of Clinical Endocrinology & Metabolism found that maintaining estradiol levels between 20–30 pg/mL supports better metabolic and bone health in men on TRT, suggesting that complete estrogen suppression is undesirable. Zinc deficiency is also well-known to adversely affect male fertility, likely by altering the ratio of testosterone to estrogen.

Screening and on-treatment testosterone levels were measured using liquid chromatography–mass spectrometry (LC-MS), the current gold standard method for sex hormone measurements. At baseline, mean total and free testosterone levels were well below the lower limits of established norms in community-based samples (Bhasin et al., 2011) and both interventions effectively raised testosterone levels into the target range. Lastly, this is the first study using AI that has performed in-depth evaluation of glucose homeostasis, inflammatory markers, and evaluation of abdominal and thigh adipose tissue. Aromatase inhibitors (AIs) are medications commonly used by men to treat hormone-sensitive conditions such as breast cancer or gynecomastia.

• Together, these products can significantly increase anabolic muscle growth, leading to a leaner physique, greater energy, and superior recovery from intense training.
• PSA90 was reached at 3 months by 52% of patients who started treatment for mCSPC with APA + ADT, versus 48% who started treatment with ENZ + ADT, 45% with AAP + ADT, and 33% with CAB/ADT (Fig. 4).
• The study does have limited external validity as data were obtained from a single institution and single provider.

Best Aromatase Inhibitors For Men (2025 Updated)

After 12 months of study, fasting glucose and insulin levels were not altered by any of the treatments. This suggests that insulin sensitivity at the level of the liver was not influenced by either of the treatment arms. Furthermore, the total AUC https://newtonschools.sch.qa/uncategorized/naposim-10-mg-vermodje/ for glucose during OGTT also did not differ between the groups. These findings suggest that estradiol is a modulator of muscle insulin sensitivity and are consistent with some animal studies showing that estrogen receptor-α is important for insulin action (Ribas et al., 2010).

Estrogen is a hormone that is not only prevalent in females, but also plays an important role in male physiology. The role of estrogen in men has received much attention since the evolving popularity of testosterone replacement therapy (TRT). It is well known that men on TRT will have a corresponding rise in their estrogen level. Monitoring and managing estrogen levels is paramount to optimizing testosterone therapy results. How long you continue aromatase inhibitors depends on your specific situation.

Muscle Strength and Symptoms of Hypogonadism

A study by Finkelstien et al. on men given GnRH to abolish endogenous testosterone production then treated with testosterone plus/minus AI demonstrated that testosterone is the primary regulator of lean mass while estradiol regulates fat mass in men (35). In addition, studies on hypogonadal men have shown a correlation between changes in testosterone levels and changes in lean mass (36). In our report despite a mean of 5 kg difference in weight loss (with AI+WL having greater weight loss compared to placebo), there was no difference in lean mass loss between the 2 groups. Estrogen is the main sex hormone regulating fat mass not only in women, but also in men (35).

According to our finding, AI+WL therapy does not cause major side effects on bone health. These drugs disrupt hormone production in the body and may increase estrogen. Higher levels of estrogen can cause males to develop gynecomastia, which is the enlargement of the breast glands. Aromatase inhibitors work by suppressing the activity of the enzyme aromatase, which activates aromatization, a process that involves the conversion of androgen and testosterone into different forms of estrogen.

Testosterone Replacement Therapy (TRT) is a common treatment for men experiencing symptoms of low testosterone. However, TRT sometimes increases estrogen levels, leading to potential side effects. To manage this, aromatase inhibitors (AIs) are often prescribed alongside TRT to prevent the conversion of testosterone to estrogen. Age-related changes contribute to increased androgen conversion, raising estrogen levels in older men. This shift has been linked to gynecomastia and reduced testosterone bioavailability. Obesity also correlates with higher aromatase expression due to its abundance in adipose tissue, exacerbating estrogen dominance and hypogonadism.